Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment.

MLA

O’Connell, Brenda C., et al. “Eganelisib Combined with Immune Checkpoint Inhibitor Therapy and Chemotherapy in Frontline Metastatic Triple-Negative Breast Cancer Triggers Macrophage Reprogramming, Immune Activation and Extracellular Matrix Reorganization in the Tumor Microenvironment.” Journal for Immunotherapy of Cancer, vol. 12, no. 8, Aug. 2024. EBSCOhost, https://doi.org/10.1136/jitc-2024-009160.

APA

O’Connell, B. C., Hubbard, C., Zizlsperger, N., Fitzgerald, D., Kutok, J. L., Varner, J., Ilaria, R., Jr, Cobleigh, M. A., Juric, D., Tkaczuk, K. H. R., Elias, A., Lee, A., Dakhil, S., Hamilton, E., Soliman, H., & Peluso, S. (2024). Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment. Journal for Immunotherapy of Cancer, 12(8). https://doi.org/10.1136/jitc-2024-009160

Chicago

O’Connell, Brenda C, Charley Hubbard, Nora Zizlsperger, Donna Fitzgerald, Jeffrey L Kutok, Judith Varner, Robert Ilaria Jr, et al. 2024. “Eganelisib Combined with Immune Checkpoint Inhibitor Therapy and Chemotherapy in Frontline Metastatic Triple-Negative Breast Cancer Triggers Macrophage Reprogramming, Immune Activation and Extracellular Matrix Reorganization in the Tumor Microenvironment.” Journal for Immunotherapy of Cancer 12 (8). doi:10.1136/jitc-2024-009160.